Key Takeaways
- OSE is developing the therapeutic cancer vaccine Tedopi in Phase III and IL-7 antagonist lusvertikimab for ulcerative colitis in Phase II.
OSE Immunotherapeutics is developing two late-stage assets in different therapeutic areas, cancer and ulcerative colitis, and has a pipeline of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?